Pediatric Interventional Cardiology Market worth $1,379.1 Million by 2018

Wednesday 16 April 2014, Amsterdam

This report studies the global pediatric interventional cardiology market over the forecast period of 2013 to 2018. This market is valued at an estimated $894.7 million in 2013 and is poised to grow at a CAGR of 9.0% from 2013 to 2018.

Various new procedures and interventional devices are being developed and launched in the market, which is a major reason for the rapid growth of this market. Companies are heavily investing in R&D, to develop new and advanced devices that cater to the unmet needs of pediatric patients. Furthermore, the high growth potential of the transcatheter heart valves market is another factor that is propelling the growth of this market. Based on device type, the ASD, VSD, and PFO devices market accounted for the largest share of 28% in 2013. However, the transcatheter pulmonary valve market is poised to grow at the highest CAGR from 2013 to 2018.

Based on geography, the global pediatric interventional cardiology market is segmented into North America, Europe, APAC, and the Rest of the World (RoW). Europe accounts for the largest share of the pediatric interventional cardiology market; the large share of this region is attributed to factors such as the large number of approved interventional cardiology devices present in the European market, investments by venture capitalists, and collaborations among key players in the market.

The major players in the pediatric interventional cardiology market are St. Jude Medical, Inc. (U.S.), Medtronic, Inc. (U.S.), W.L. Gore & Associates, Inc. (U.S.), Edwards Lifesciences Corp (U.S.), NuMED, Inc. (U.S.), Cordis Corporation (U.S.), GE Healthcare (U.K), Siemens Healthcare (Germany), Boston Scientific (U.S.), and Abbott Vascular (U.S.), among others.